The next life-changing treatment may already
be in your blood.

Autoantibodies (anti-self) naturally develop in patients and can play a dramatic role in disease outcomes behind the scenes. However, the role of autoantibodies has been understudied due to technological limitations. Seranova’s new REAP technology breaks through these limitations, revealing the next generation of therapeutics circulating in patients’ own blood.

Autoantibodies are key drivers of health & disease.


8% of patients with Rheumatoid Arthritis (RA) are reported to generate anti-TNFa autoantibodies. These patients benefit from significantly reduced symptoms (erosions of hands or feet).


15% of invasive breast carcinoma patients are reported to produce their own anti-Her-2 autoantibodies.  Patients with these protective autoantibodies benefit from significantly higher likelihood of recurrance-free survival.


Healthy individuals commonly produce high affinity anti-α-synuclein autoantibodies.  Patients with Parkinson's and Multiple System Atrophy (MSA) report significantly lower levels of these protective autoantibodies.

What if we could dramatically increase our understanding of how autoantibodies shape disease outcomes?

Unlock the next life
changing treatment.

Natural clinical trials occur when a fraction of patients develop autoantibodies to a specific target.  If patients with a specific autoantibody reactivity benefit from lessened disease severity or better outcomes, a therapeutic antibody with the same reactivity may benefit other patients.

Our proprietary technology generates the most accurate and extensive collection of these "studies" ever assembled, effectively giving Seranova and our collaborators exclusive access to the results. Targets validated by these “natural trials" will fuel Seranova's pipeline of first-in-class therapeutics.

Why Seranova

Seranova Therapeutics:
Inspired by patients’ protective autoantibodies

See how our technology is generating the next generation of therapeutics
Our technology